Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line treatment of chronic graft-versus-host disease with ciclosporine, prednisone and rituximab
2009-016898-14Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by CHU de Nantes. Primary endpoint: Response rate at 12 months. Started Mar 2010; status: active.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2009-016898-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016898-14.